2023
Risk Prediction for Heart Failure Patients Admitted to the Intensive Care Unit Insights From REVeAL-HF
O’Connor K, Yamamoto Y, Sen S, Samsky M, Wilson F, Desai N, Ahmad T, Fuery M. Risk Prediction for Heart Failure Patients Admitted to the Intensive Care Unit Insights From REVeAL-HF. JACC Heart Failure 2023, 11: 727-728. PMID: 37052546, DOI: 10.1016/j.jchf.2023.01.021.Peer-Reviewed Original Research
2021
Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial
Berg DD, Samsky MD, Velazquez EJ, Duffy CI, Gurmu Y, Braunwald E, Morrow DA, DeVore AD. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. Circulation Heart Failure 2021, 14: e007034. PMID: 33530704, PMCID: PMC7908815, DOI: 10.1161/circheartfailure.120.007034.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAminobutyratesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBiphenyl CompoundsCardiotonic AgentsCardiovascular DiseasesChronic DiseaseDrug CombinationsEnalaprilGlomerular Filtration RateHeart FailureHospitalizationHumansHyperkalemiaHypotensionIntensive Care UnitsNatriuretic Peptide, BrainPeptide FragmentsRenal InsufficiencyRiskValsartanConceptsAcute decompensated heart failureSacubitril/valsartanDecompensated heart failureHeart failureCardiovascular deathHigh-risk subpopulationsIndex hospitalizationSymptomatic hypotensionRenal functionSafety outcomesBaseline systolic blood pressureBaseline NT-proBNPPIONEER-HF trialDouble-blind trialHigh-risk patientsGlomerular filtration rateSystolic blood pressureHigh-risk subgroupsRelative risk reductionRisk-benefit profileLow-risk subgroupsHospital initiationInotrope usePIONEER-HFNT-proBNP